We are live on !
Find out more
VA
Verdad Advisers Portfolio holdings
AUM
$104M
Turnover
59.06%
This Fund
S&P 500
This Quarter Est. Return
+21.07%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$104M
AUM Growth
+$15.6M
(+18%)
Cap. Flow
+$3.28M
Cap. Flow % of AUM
Cap. Flow %
3.14%
Top 10 Holdings %
Top 10 Hldgs %
18.12%
Holding
276
New
97
Increased
59
Reduced
42
Closed
66
Avg Time Held
0.3
years
Top 10 Avg Time Held
0.1
years
Top 20 Avg Time Held
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.13M |
| 2 |
Protara Therapeutics
TARA
|
+$1.49M |
| 3 |
X4 Pharmaceuticals
XFOR
|
+$1.44M |
| 4 |
Tyra Biosciences
TYRA
|
+$1.19M |
| 5 |
Jade Biosciences
JBIO
|
+$1.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$2.57M |
| 2 |
Revolution Medicines
RVMD
|
+$2.56M |
| 3 |
State Street
STT
|
+$2.11M |
| 4 |
Autohome
ATHM
|
+$2.11M |
| 5 |
Cal-Maine
CALM
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.7% |
| 2 | Technology | 15.71% |
| 3 | Financials | 9.07% |
| 4 | Communication Services | 7.06% |
| 5 | Consumer Discretionary | 5.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Apple
AAPL
$5.01T
| $2.15M | 2.06% |
+7,445
| New | +$2.13M |
2026 Q2
0 quarters
|
|
2
Belite Bio
BLTE
$5.94B
| $2.12M | 2.03% |
13,758
-55
| -0.4% | -$8.43K |
2026 Q1
1 quarter
|
|
3
Acadia Pharmaceuticals
ACAD
$3.39B
| $2.09M | 2% |
82,629
+14,339
| +21% | +$315K |
2026 Q1
1 quarter
|
|
4
Comcast
CMCSA
$78.5B
| $2.08M | 1.99% |
84,569
+43,020
| +104% | +$1.11M |
2025 Q4
2 quarters
|
|
5
Chatham Lodging
CLDT
$657M
| $1.85M | 1.77% |
140,000
| – | – |
2025 Q4
2 quarters
|
|
6
Tenax Therapeutics
TENX
$56.5M
| $1.79M | 1.72% |
123,174
+27,844
| +29% | +$356K |
2026 Q1
1 quarter
|
|
7
Slide Insurance Holdings
SLDE
$3.17B
| $1.76M | 1.69% |
91,070
+60,412
| +197% | +$1.09M |
2026 Q1
1 quarter
|
|
8
Zymeworks
ZYME
$1.83B
| $1.74M | 1.67% |
66,688
-16,010
| -19% | -$407K |
2026 Q1
1 quarter
|
|
9
AMN Healthcare
AMN
$1.61B
| $1.68M | 1.61% |
51,906
+1,906
| +4% | +$49.2K |
2025 Q4
2 quarters
|
|
|
10
X4 Pharmaceuticals
XFOR
$277M
| $1.64M | 1.57% |
+352,093
| New | +$1.44M |
2026 Q2
0 quarters
|
|
11
Versant Media Group
VSNT
$4.41B
| $1.57M | 1.5% |
43,503
+24,506
| +129% | +$984K |
2026 Q1
1 quarter
|
|
12
NETSCOUT
NTCT
$2.81B
| $1.44M | 1.38% |
33,128
+18,406
| +125% | +$693K |
2026 Q1
1 quarter
|
|
13
Whitehawk Therapeutics
WHWK
$174M
| $1.38M | 1.32% |
301,483
+185,999
| +161% | +$774K |
2026 Q1
1 quarter
|
|
14
Johnson & Johnson
JNJ
$613B
| $1.37M | 1.31% |
5,384
-34
| -0.6% | -$7.92K |
2024 Q1
9 quarters
|
|
15
Contineum Therapeutics
CTNM
$259M
| $1.33M | 1.27% |
81,014
-5,018
| -6% | -$65.8K |
2026 Q1
1 quarter
|
|
|
16
Jade Biosciences
JBIO
$875M
| $1.25M | 1.2% |
+56,384
| New | +$1.18M |
2026 Q2
0 quarters
|
|
17
Cisco
CSCO
$422B
| $1.21M | 1.16% |
+10,307
| New | +$1.08M |
2026 Q2
0 quarters
|
|
18
Nurix Therapeutics
NRIX
$2.75B
| $1.2M | 1.15% |
49,511
-33,914
| -41% | -$578K |
2026 Q1
1 quarter
|
|
|
19
Protara Therapeutics
TARA
$141M
| $1.19M | 1.14% |
+312,249
| New | +$1.49M |
2026 Q2
0 quarters
|
|
20
Bloomin' Brands
BLMN
$842M
| $1.19M | 1.14% |
130,000
+30,000
| +30% | +$218K |
2025 Q4
2 quarters
|
|
|
21
Tyra Biosciences
TYRA
$1.32B
| $1.15M | 1.1% |
+36,003
| New | +$1.19M |
2026 Q2
0 quarters
|
|
22
Par Pacific Holdings
PARR
$4.14B
| $1.12M | 1.07% |
20,000
-2,500
| -11% | -$149K |
2026 Q1
1 quarter
|
|
23
Edgewise Therapeutics
EWTX
$4.13B
| $1.11M | 1.06% |
27,234
+14,182
| +109% | +$489K |
2026 Q1
1 quarter
|
|
24
Alphabet (Google) Class A
GOOGL
$4.22T
| $1.04M | 0.99% |
+2,900
| New | +$1.04M |
2026 Q2
0 quarters
|
|
25
Carter's
CRI
$1.2B
| $1.03M | 0.99% |
25,000
| – | – |
2025 Q4
2 quarters
|
|
Similar funds
IAP
TPW
ACM
TOTUOP
ICVCFVA
2L
KFI
GAM
Verdad Advisers's Q2 2026 Portfolio in Review
As of Q2 2026, Verdad Advisers held 276 positions worth $104M, up 18% from $88.8M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Verdad Advisers deployed $3.28M of net new capital in Q2 2026, opening 97 new positions and adding to 59 existing holdings. Its largest new stake was Apple: 7,445 shares worth $2.15M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 42% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Micron Technology, an estimated $2.57M trimmed.
- Verdad Advisers's largest Q2 2026 buy was Apple: 7,445 shares worth $2.15M.
- Verdad Advisers added most to Comcast in Q2 2026, an estimated $1.11M increase.
- Verdad Advisers's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $2.57M.
- Verdad Advisers fully exited State Street in Q2 2026, selling an estimated $2.11M.
- Verdad Advisers's ten largest holdings make up 18% of its $104M portfolio in Q2 2026.
- Verdad Advisers opened 97 new positions and closed 66 in Q2 2026.
- Verdad Advisers's portfolio value rose 18% quarter-over-quarter to $104M.
Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.